Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Short term Debt (2017 - 2025)

Aytu Biopharma (AYTU) has disclosed Short term Debt for 14 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Short term Debt changed 0.0% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 0.0% change, with the full-year FY2025 number at $1.9 million, down 22.46% from a year prior.
  • Short term Debt was $1.9 million for Q4 2025 at Aytu Biopharma, down from $14.9 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $15.1 million in Q1 2024 to a low of $39000.0 in Q4 2023.
  • A 5-year average of $4.3 million and a median of $1.9 million in 2024 define the central range for Short term Debt.
  • Biggest YoY gain for Short term Debt was 10303.0% in 2023; the steepest drop was 99.48% in 2023.
  • Aytu Biopharma's Short term Debt stood at $1.2 million in 2021, then skyrocketed by 516.0% to $7.4 million in 2022, then plummeted by 99.48% to $39000.0 in 2023, then surged by 4661.54% to $1.9 million in 2024, then changed by 0.0% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Short term Debt are $1.9 million (Q4 2025), $14.9 million (Q3 2025), and $1.9 million (Q2 2025).